The authors thank all patients and blood donors who participated in this study and gratefully acknowledge Dr. H. Olthuis and his staff at the Red Cross Blood Bank of Nijmegen for collecting blood samples from the donors.
Zinc and copper levels in whole blood and plasma from patients with squamous cell carcinomas of head and neck
โ Scribed by M. Abdulla; A. Biorklund; A. Mathur; K. Wallenius
- Publisher
- John Wiley and Sons
- Year
- 1979
- Tongue
- English
- Weight
- 307 KB
- Volume
- 12
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
โฆ Synopsis
Zinc in plasma and whole blood from 13 patients with squamous cell carcinoma of the head and neck was significantly decreased, and the copper:zinc ratio in the plastna was significantly higher than in healthy controls.
The plasma zinc was significantly lower in patients who did not respond to therapy and who died within 12 months than in those who responded t o therapy and had a remission within 12-1 5 months. In patients responding t o therapy and alive after 12-15 months, zinc in the plasma and whole blood and the copper:zinc ratio became normal.
the plasma and whole blood and the copper:zinc ratio in squamous cell carcinoma o f the head and neck.
These results suggest a potential screening and predicting value of zinc in .
๐ SIMILAR VOLUMES
## Abstract ## Background. We evaluated the concentrations of glutathione and uric acid, low molecular weight antioxidants, in saliva of patients with head and neck squamous cell carcinoma (HNSCC), in order to identify differences with normal subjects and to obtain information about biochemical al
## Abstract ## Background. Treatment of head and neck squamous cell carcinoma (HNSCC) addresses the primary tumor and the lymphatic drainage. Modalities for the neck are neck dissection and/or radiation therapy. In most cases, the neck is treated by the modality that seems more appropriate for the
## Abstract ## Background Despite improvements in locoregional treatment of stages III/IV squamous cell carcinoma of the head and neck (HNSCC), local and distant failure rates remain high. An effective adjuvant therapy is required for these patients. Among novel approaches is radioimmunotherapy, i